DMAC — DiaMedica Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $340.11m
- $310.10m
- 41
- 11
- 95
- 47
Annual cashflow statement for DiaMedica Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.3 | -13.6 | -13.7 | -19.4 | -24.4 |
| Depreciation | |||||
| Non-Cash Items | 1.89 | 1.78 | 1.55 | 0.53 | 0.817 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.2 | -0.461 | 0.585 | 0.093 | 1.51 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -9.19 | -12.3 | -11.5 | -18.7 | -22.1 |
| Capital Expenditures | -0.047 | -0.022 | -0.081 | -0.024 | -0.025 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16.1 | -20.5 | 11.6 | -18.3 | 8.59 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -16.1 | -20.5 | 11.5 | -18.3 | 8.56 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.8 | 30.1 | -0.006 | 36.8 | 12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.53 | -2.7 | 0.021 | -0.185 | -1.52 |